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Background: mRNA levels of members of the Vascular Endothelial Growth Factor family (VEGF-A, -B, -C, -D,
Placental Growth Factor/PlGF) have been investigated as tissue-based markers of colon cancer. These studies, which
used specimens obtained by surgical resection or colonoscopic biopsy, yielded contradictory results. We studied
the effect of the sampling method on the marker accuracy of VEGF family members.
Methods: Comparative RT-qPCR analysis was performed on healthy colon and colon carcinoma samples obtained
by biopsy (n = 38) or resection (n = 39) to measure mRNA expression levels of individual VEGF family members.
mRNA levels of genes encoding the eicosanoid enzymes cyclooxygenase 2 (COX2) and 5-lipoxygenase (5-LOX) and
of genes encoding the hypoxia markers glucose transporter 1 (GLUT-1) and carbonic anhydrase IX (CAIX) were
included as markers for cellular stress and hypoxia.
Results: Expression levels of COX2, 5-LOX, GLUT-1 and CAIX revealed the occurrence in healthy colon resection
samples of hypoxic cellular stress and a concurrent increment of basal expression levels of VEGF family members.
This increment abolished differential expression of VEGF-B and VEGF-C in matched carcinoma resection samples and
created a surgery-induced underexpression of VEGF-D. VEGF-A and PlGF showed strong overexpression in carcinoma
samples regardless of the sampling method.
Conclusions: Sampling-induced hypoxia in resection samples but not in biopsy samples affects the
marker-reliability of VEGF family members. Therefore, biopsy samples provide a more accurate report on VEGF
family mRNA levels. Furthermore, this limited expression analysis proposes VEGF-A and PlGF as reliable, sampling
procedure insensitive mRNA-markers for molecular diagnosis of colon cancer.
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Colorectal cancer is the second most commonly diag-
nosed cancer in females and the third in males. It is the
second leading cause of cancer-related death [1]. World-
wide, it accounts for over 1.2 million new cases every
year, and in 2008 it caused about 608,700 deaths. Colon
carcinoma evolves from a premalignant adenoma pre-
cursor stage or polyp. The progression from adenoma to* Correspondence: Johan.Grooten@ugent.be
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reproduction in any medium, provided the orcarcinoma is a multistep process involving cumulative
genetic and epigenetic alterations in proto-oncogenes,
tumor suppressor genes and DNA repair genes [2-4].
Colon carcinoma tissue samples have been intensively
studied in search for tissue-based diagnostic, prognostic
and predictive markers. Samples are routinely obtained
by two different clinical procedures. During colonos-
copy, which is the gold standard for detection of colon
carcinoma and adenoma, biopsies of polyp-like extru-
sions are obtained for pathological examination, and
these extrusions are removed whenever possible. In sur-
gical resection, carcinoma-like outgrowths are removed
by cutting out part of the colon containing the suspectedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, little is known about the impact of the sam-
pling method on the overall condition of the sampled
tissue or the expression levels of potential cancer bio-
marker genes.
Vascular Endothelial Growth Factor (VEGF; VEGF-A)
has long been proposed as a biomarker for cancer as well
as a target for anti-angiogenic cancer therapy. Several
studies consistently showed elevated VEGF-A expression
levels in most solid tumors, including colon carcinoma
[5-9]. Furthermore, these elevated expression levels have
been correlated with tumor progression [10-12]. VEGF-
A is an inflammation and hypoxia responsive gene, and
its biomarker function is believed to be related to the
hypoxic growth conditions characteristically associated
with rapidly growing solid tumors and to its ability to
promote the development of new vasculature [11,13].
Fewer studies addressed the mRNA expression levels
in colon cancer of the other VEGF family members:
VEGF-B, VEGF-C, VEGF-D and Placental Growth Factor
(PlGF). Furthermore, some of these studies reported
contradictory results. As such, similar expression levels
of VEGF-C in healthy and carcinoma tissue were
reported in three studies [5,8,14]. However, other studies
reported higher levels [6,7] that were correlated with
lymph node metastasis and poor prognosis [8].
We believe that some of these controversial findings
might have resulted from the use of different types of
colon tissue samples. Several studies performed expres-
sion analysis on samples obtained during surgical resec-
tion [5,7,8]. Others used biopsies obtained during
colonoscopy [14] or did not specify the sampling
method [6]. Yet, both sampling procedures differ strik-
ingly; the acquirement of colon biopsies requires only
minutes, whereas during surgical resection part of the
colon is clamped off for a considerable length of time.
To examine to what extent the sampling procedure may
affect VEGF gene expression, we analyzed mRNA ex-
pression levels of all five VEGF family members in colon
carcinoma samples obtained by biopsy and in others
obtained by surgical resection. mRNA expression levels
in healthy colon tissue of the eicosanoid enzymes,
cyclooxygenase 2 (COX2) and 5-lipoxygenase (5-LOX),
were included as markers of cellular stress induced by
inflammation, tissue damage and/or hypoxia [15-19]. In
addition, mRNA expression levels of glucose transporter
1 (GLUT-1) and carbonic anhydrase IX (CAIX) were
included as markers of hypoxia [20,21].
Results
Surgical resection induces hypoxic cellular stress in
healthy colon tissue
To examine to what extent the sampling procedure
(biopsy versus surgical resection) may affect the overallcondition of the sampled tissue, we analyzed the mRNA
expression of COX2 and 5-LOX in samples of healthy
colon tissue. As shown in Figure 1A, expression levels of
COX2, an inflammation and hypoxia responsive gene
used here as a biomarker of cellular stress, were signifi-
cantly higher in resections than in biopsies. Also the ex-
pression levels of GLUT-1 and CAIX, two hypoxia
markers, were significantly increased in resected samples
compared to biopsy samples (Figure 1C-D). Finally, the
expression levels of 5-LOX, included here as a control
gene induced by cellular stress but insensitive to hyp-
oxia, were identical in the two groups of samples
(Figure 1B). Combined, these results indicate the induc-
tion by the surgical resection procedure of hypoxic cel-
lular stress in the resected tissue.
Surgical resection increases expression levels of VEGF
family members in healthy colon tissue
We next determined whether the occurrence of surgery-
related hypoxic stress in resected healthy tissue samples
was reflected in the expression levels of the individual
VEGF family members. As shown in Figure 2, highly sig-
nificant (p < 0.001) differences between resected and bi-
opsy healthy colon samples were observed for all the
VEGF family members. For these genes, the median ex-
pression levels were two- to three-fold (VEGF-A, -B, -C
and PlGF) higher in resected than in biopsy samples, up
to a striking 22-fold increase for VEGF-D.
The sampling procedure affects the biomarker read-out
of VEGF family members
We next assessed the extent to which the sampling-
induced differences in VEGF gene expression observed
in healthy tissue affected the magnitude of the difference
between healthy and carcinoma tissue. To that end, we
compared VEGF gene induction in colon carcinoma to
matched healthy tissue samples obtained by biopsy or by
surgical resection. Expression levels of VEGF-A were sig-
nificantly induced in carcinoma tissues towards healthy
tissues independent of the sampling method (Figure 3A).
However, for the other VEGF family members, the mag-
nitude of the difference between healthy and carcinoma
tissue in resection samples was affected by the incre-
ment of expression in healthy tissue caused by the surgi-
cal sampling procedure. For VEGF-B,VEGF-C and PlGF,
this resulted in reduced expression differences between
healthy and carcinoma tissue in resected samples
(Figure 3B, C and E). The consequences are most pro-
nounced for VEGF-B that albeit significantly induced in
biopsy carcinoma samples, no longer showed signifi-
cance in carcinoma samples obtained by surgical resec-
tion (Figure 3B). A similar sampling procedure induced
turnaround of biomarker value is observed for VEGF-D,
although in an opposite direction. Here, the pronounced
A B
C D
Figure 1 Effect of sampling method on the expression of inflammatory and hypoxic stress responsive genes in healthy colon tissue
samples. Relative mRNA expression levels of the inflammatory eicosanoid enzymes COX2 (A) and 5-LOX (B) and of the hypoxia markers GLUT-1
(C) and CAIX (D) are shown for healthy colon biopsies and healthy colon resection samples. Expression levels were normalized against reference
genes TBP and SDHA and were scaled against the median of the biopsy samples (median set to 1). Expression data are depicted as scatter plots
of the values obtained for each individual sample. The horizontal line represents the median; ns: not significant; *: p < 0.05; **: p < 0.01; ***: p <
0.001 with Mann–Whitney U Test.
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tissue as opposed to the near absence of such an in-
crease in carcinoma tissue resulted in a highly significant
underexpression of VEGF-D in carcinoma resection
samples (Figure 3D). On the contrary, in biopsy samples
no difference in VEGF-D expression between healthy
colon and colon carcinoma samples was observed.
Cancer biomarker accuracy of VEGF family members
Receiver-operating characteristics (ROC) analysis is
commonly used to assess the reliability and accuracy of
potential biomarkers. ROC-based assessment of the indi-
vidual VEGF family members as biomarkers for colon
cancer identified overexpression of PlGF (AUC 0.9342)
as the most effective mRNA-marker for samples
obtained by biopsy with VEGF-A (AUC 0.8760) and
VEGF-C AUC 0.8977) following as close seconds
(Figure 4). This ranking however changes dramatically
when considering samples obtained by resection. Here,
underexpression of VEGF-D emerges as the most potent
biomarker with an AUC of 0.9047 (p < 0.0001) and a
ROC-curve significantly different (p < 0.0001) from thebiopsy curve (Figure 4D). Overexpression of VEGF-A
(AUC 0.8573) now precedes PlGF (AUC 0.8231), VEGF-
C (AUC 0.6200) and especially VEGF-B (AUC 0.5621)
shows strongly reduced accuracy as colon cancer
mRNA-marker (Figure 4).
Discussion
Biomarker expression profiles have become a valuable
tool in diagnostic research, patient management and
cancer therapy. We explored the influence of different
sampling methods on the expression of VEGF family
biomarkers in colon cancer. Samples obtained by either
biopsy or surgical resection were compared for the
differential expression of VEGF-A, VEGF-B, VEGF-C,
VEGF-D and PlGF. To examine the occurrence of cellu-
lar stress caused by the sampling procedure, the expres-
sion levels of the eicosanoid enzymes COX2 and 5-LOX
were quantified in healthy colon tissue. COX2 is a key
inflammatory enzyme, and its expression is strongly
induced by NF-κB and HIF-1 transcription factors in re-
sponse to inflammatory insults and hypoxic growth con-
ditions, respectively [19,22-26]. In contrast, expression
Figure 2 Effect of sampling method on the expression of VEGF family members in healthy colon tissue samples. Relative mRNA
expression levels of VEGF-A (A), VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) are shown for healthy colon biopsies and healthy colon resection
samples. Expression levels were normalized against reference genes TBP and SDHA and were scaled against the median of the biopsy samples
(median set to 1). Expression data are depicted as scatter plots of the values obtained for each individual sample. The horizontal line represents
the median; ***: p < 0.001 with Mann–Whitney U Test.
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induced by various inflammatory insults [19,27,28].
Strikingly, we observed a pronounced expression incre-
ment of COX2 in healthy colon resection samples rela-
tive to healthy biopsy samples. This was not the case for
5-LOX. This differential expression pattern of COX2 as
opposed to 5-LOX indicates that considerably more hyp-
oxic stress may be present in resection samples than in
samples obtained by biopsy. The presence of hypoxia in
resection samples was further substantiated by theFigure 3 Influence of sampling method on the biomarker read-out of
of VEGF-A (A), VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) are shown.
of the carcinoma sample against the expression value of the paired health
the whiskers represent minimum and maximum ratios. ns: not significant; *significantly increased expression in resection samples of
the hypoxia markers GLUT-1 and CAIX. There is a large
difference in the time needed to obtain samples by the
two procedures. Whereas the collection of colon biop-
sies requires only minutes, surgical resection takes 30 to
90 minutes, during which the colon is clamped off. This
cuts off blood circulation and oxygen delivery and could
cause hypoxia in the clamped colon. The observed incre-
ment in COX2, GLUT-1 and CAIX mRNA levels in
healthy colon tissue resections might therefore be aVEGF family members. n-Fold induction levels in carcinoma samples
The n-fold induction value represents the ratio of the expression value
y sample. The box represents the median with interquartile range and
:p < 0.05; ***: p < 0.001 with Wilcoxon signed-rank test.
Figure 4 ROC-analysis of the biomarker accuracy of VEGF family members for biopsy and resection samples. ROC-curves of VEGF-A (A),
VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) are shown for biopsy and resection samples. The ROC-curves represent the sensitivity and
specificity of the individual VEGF family members as colon carcinoma biomarkers. The insert gives the area under the curve (AUC), which
quantifies the ability of the marker to distinguish between healthy colon and colon carcinoma. The accompanying p-value tests the null
hypothesis, namely, that the AUC equals 0.50 and thus the biomarker is incompetent. The identity-line (Identity%) represents the null hypothesis.
*: p < 0.05; ***: p < 0.001 calculated with the method of DeLong et al. [35].
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inducing a hypoxic stress signal.
VEGF-A is readily induced by COX2 derived prosta-
glandins such as PGE2 [29,30]. Concomitant with the
clear induction of COX2 mRNA in resected healthy tis-
sue, VEGF-A expression levels were increased in healthy
tissue resections. However, besides VEGF-A also other
VEGF family members showed significant mRNA ex-
pression increments in resected healthy tissue ranging
from 2–3 fold (VEGF-B, VEGF-C, PlGF) up to 22-fold
(VEGF-D). Two recent reports described the induction
during hypoxia of these VEGF family members in lung
and lymphatic endothelial cells [31,32]. It is therefore
likely that the combined action of clamping-induced
hypoxia and COX2 derived prostaglandins are at the
basis of the increased mRNA expression of VEGF-A as
well as of the other VEGF family members we observed
in resected healthy colon samples.
A determining factor in defining a biomarker is its
accuracy in differentiating a healthy from a diseasedstate. Therefore, we assessed the ability of the individ-
ual VEGF members to discriminate between healthy
and cancerous colon tissue and the influence of the
sampling method on this ability. Although the cohort
size (n=77) so far is rather limited, VEGF-A and PlGF
emerged as potential mRNA-markers discriminating
with relatively high accuracy between healthy and car-
cinoma tissue in samples obtained by biopsy or by sur-
gical resection. Our results confirm previous studies
reporting significantly increased expression levels of
VEGF-A in colon carcinoma samples compared to
healthy tissue [5-9]. The same conclusion holds true
for PlGF. Of all VEGF family members, PlGF emerged
from our ROC-analysis as the most accurate biomarker
in both the sampling methods and was even more ac-
curate than VEGF-A in biopsies. It is therefore re-
markable that PlGF has received less attention than
other VEGF members in colon carcinoma. Wei and
colleagues studied resection samples from colorectal
carcinoma patients and also documented increased
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with reduced survival [9]. A similar result was
obtained for both PlGF isoforms, PlGF-1 and PlGF-2,
by Escudero-Esparza and colleagues [33]. Our observa-
tions further confirm these findings.
For VEGF-B, VEGF-C and VEGF-D we observed a sig-
nificant impact of the sampling procedure on the mRNA
expression levels in healthy versus colon carcinoma tis-
sues. Table 1 compares our observations with previously
reported data taking into account the reported sampling
method but also other potential confounding factors
such as the inclusion or not of rectal samples.
Previous studies did not reveal overexpression of
VEGF-B in colon carcinoma (Table 1). Also we did not
observe increased VEGF-B mRNA levels in samples
obtained by surgical resection. However, this lack of
overexpression appears to be a consequence of the surgi-
cal sampling method rather than a characteristic intrin-
sic to colon carcinoma. This conclusion is based on the
pronounced expression increment we observed in car-
cinoma tissue obtained by colonoscopic biopsy. These
opposite results clearly identify the strong impact of the
sampling procedure on VEGF-B mRNA-levels and chal-
lenge the conclusions of previous studies using samples
obtained by surgical resection [5,7,8]. VEGF-C resembles
VEGF-B in the impact of the clinical sampling method,
showing a weak overexpression in resections as opposed
to a pronounced, highly significant overexpression in bi-
opsies (Table 1). Two out of five previously publishedTable 1 Comparison of expression data for VEGF-B, VEGF-C a
VEGF
family
member
Own data
Δ expression Δ expres
Resection Biopsy
VEGF-B = ↗ *** =
=
=
VEGF-C ↗ * ↗ *** =
↗
↗
=
=
VEGF-D ↘ *** = ↘
↘
↘
↘
Δ expression: differential expression in carcinoma samples compared to healthy tiss
↗: significantly increased.
↘: significantly decreased.
=: no significance.
n.s.: not specified.
Rectal incl.: rectal samples included in the analysis.
*: p<0.05 with Wilcoxon signed rank test.
***: p<0.001 with Wilcoxon signed rank test.reports similarly documented increased VEGF-C expres-
sion levels. Other reports using either biopsy or resected
material failed however to detect significant changes.
These conflicting data may be due to confounding fac-
tors other than the sampling method, namely the inclu-
sion of rectal samples in these studies. Because
radiotherapy prior to surgery is standard procedure in
rectal cancer, we excluded such patients from our study.
Finally, also VEGF-D shows a strong impact of the sam-
pling method on its differential mRNA expression
(Table 1). Here however, resected tissue samples show a
pronounced underexpression as opposed to the absence
of a differential expression in biopsy samples. This
surgery-created signature again emphasizes the import-
ance of taking into account the clinical procedure used
for colon tissue sampling when performing colon cancer
expression studies.
Our study included a total of 77 patients. Though this
is a large cohort, clearly it is not large enough to exclude
biases due to type I error. To detect type I errors, we
statistically analyzed the likelihood that group-related
disparities in gender, tumor grade, sample location and
age confounded the conclusions of our study. As shown
in the supplementary data (Additional file 1: Tables S1,
Additional file 2: Table S2, Additional file 3: Table S3,
Additional file 4: Table S4 and Additional file 5: Table
S5), we did not detect specific biases that could contrib-
ute to the observed differential gene expression patterns.
Yet, expansion of this study to a larger patient cohortnd VEGF-D with previously published reports
Published data
sion Sampling
method
Other
confounders
Refs
Resection - [5]
Resection Rectal incl. [7]
Resection Rectal incl. [8]
Resection - [5]
n.s. Rectal incl. [6]
Resection Rectal incl. [7]
Resection Rectal incl. [8]
Biopsy Rectal incl. [14]
n.s. Rectal incl. [6]
Resection Rectal incl. [7]
Resection Rectal incl. [8]
Biopsy Rectal incl. [14]
ue samples.
Table 2 Clinicopathological features of the colon
carcinoma patients
Variable Number of patients
Biopsy Resection
Sex
Male 22 25
Female 16 14
Age at diagnosis
Median age (range, years) 70 (39–85) 67 (39–84)
Site of tumor
Sigmoid 20 14
Colon descendens 2 2
Colon transversum 1 4
Hepatic flexure 1 3
Colon ascendens 5 5
Caecum and valve of Bauhin 8 7
Not specified 1 4
Tumor grade
Low 4 5
Moderate 18 24
High 9 7
Unknown 7 3
Dukes classification
Dukes’ A 3 8
Dukes’ B 15 12
Dukes’ C 6 12
Dukes’ D 13 5
Unknown 1 2
T category
T1-T2 3 8
T3-T4 26 29
Tx 9 2
Lymphatic spread
N0 18 21
N+ 10 16
Nx 10 2
Metastasis
M0 20 32
M+ 13 5
Mx 5 2
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relevance for colon cancer diagnosis and basic research.
Conclusions
Our comparative gene mRNA expression analysis of
healthy and carcinoma colon tissue shows that the sam-
pling procedure - surgical resection versus colonoscopic
biopsy - has an important impact on the read-out of
VEGF family members as potential colon cancer mRNA-
markers. The sampling-induced modulation of VEGF
gene expression profiles could be related to cellular
stress caused by hypoxia elicited in resected tissue sam-
ples by clamping of blood vessels during surgery. The
higher sensitivity of healthy tissue to surgery-induced
cellular stress compared to the relative insensitivity of
carcinoma tissue affected to different degrees the reli-
ability of individual VEGF-members as mRNA-markers
for colon carcinoma. Therefore, samples obtained by bi-
opsy provide a more reliable VEGF mRNA-marker read-
out than samples obtained by surgical resection.
Methods
Biological samples
Samples were obtained from primary colon carcinomas
either by biopsy (n=38) or by surgical resection (n = 39)
at the Ghent University Hospital. Carcinomas were
sampled in the infiltrating area of the growth, avoiding
the necrotic center. Histopathological examination con-
firmed the carcinoma state of the tissue. From each pa-
tient, a corresponding healthy colon mucosa sample was
taken from the same colon segment. None of the
patients had received chemo- or radiotherapy before sur-
gery or colonoscopy. Immediately after isolation, the bi-
opsies were placed in RNAlaterW Solution (Ambion/
Applied Biosystems, Foster City, CA). Surgical resection
samples were also placed in RNAlaterW Solution at the
end of the surgical procedure and after an initial examin-
ation by the pathologist. All samples were kept at −80°C
until RNA extraction. The clinicopathological features of
the patients are summarized in Table 2. All tissues were
obtained following informed consent of the patients and
approval of the study by the Ethics Committee of the
Ghent University Hospital.
RNA extraction, RNA quality control and cDNA synthesis
Total RNA was extracted with the RNeasy Plus mini
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. This kit contains a gDNA-
elimination step to avoid gDNA contamination. After
extraction, RNA quality and integrity was verified
using an RNA 6000 Nano Chip Kit on the Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA). Only samples with adequate quality and in-
tegrity (77/80) were used for the RT-qPCR analysis.cDNA was synthesized from 1 μg of total RNA using
SuperscriptW II reverse transcriptase (Invitrogen,
Merelbeke, Belgium) according to the manufacturer’s
instructions.
RT-qPCR
Real-time quantitative PCR (RT-qPCR) was performed
using the LC 480 Sybr Green I master kit on a
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Roche Applied Science, Penzberg, Germany). Primers
were designed using PrimerSelect (DNASTAR, Madison,
USA) and purchased from Invitrogen. The sequences of
the forward and reverse primers were as follows: VEGF-
A 5’-TGAGTTGCCCAGGAGACCAC-3’ and 5’-GAAG
GGGAGCAGGAAGAGGAT-3’; VEGF-B 5’-CCGGAA
GCTGCGAAGGTGACA-3’ and 5’-GGGAGACAAGG
GATGGCAGAAGAG-3’; VEGF-C 5’-CACGGCTTATG
CAAGCAAAGA-3’ and 5’-TCCTTTCCTTAGCTGA
CACTTGT-3’; VEGF-D 5’-GCAGCCCTAGAGAAACGTG-
3’ and 5’-AGGTGCTGGTGTTCATACAGAT-3’; PlGF 5’-
TGCGGCGATGAGAATCTGC-3’ and 5’-AGCGAACGTGCT
GAGAGAAC-3’; COX2 5’-TTGCTGGAACATGGAATTACC-
3’ and 5’-TGCCTGCTCTGGTCAATG-3’; 5-LOX 5’-
TGGCGCGGTGGATTCATAC-3’ and 5’-CAGGGGAAC
TCGATGTAGTCC-3’; GLUT-1 5’-CTTGTGTGGCCTT
CTTTGAAGT-3’ and 5’-CCACACAGTTGCTCCACAT-
3’; CAIX 5’-GGAAGGCTCAGAGACTCA-3’ and 5’-
CTTAGCACTCAGCATCAC-3’. All samples were assayed
in triplicate. Relative expression values were calculated
using the 2(−delta delta C(T)) method and were normal-
ized against reference genes: tata-binding protein (TBP)
and succinate dehydrogenase complex subunit A (SDHA)
(primers: TBP 5’-CGGCTGTTTAACTTCGCTTC-3’ and
5'-CACACGCCAAGAAACAGTGA-3’; SDHA 5’-TGGG
AACAAGAGGGCATCTG-3’ and 5’-CCACCACTGCAT
CAAATTCATG-3’). In these calculations we took into ac-
count the PCR efficiency of the individual PCR reactions,
calculated on the basis of linear regression as described in
Ruijter et al. [34]. For the comparison between healthy
colon biopsies and resections, the normalized relative ex-
pression values were scaled against the median of the
healthy biopsies (median of biopsies set to 1). The specifi-
city of amplification was confirmed by evaluation of the
melting curves.Statistical analysis
Statistical analysis was performed using the GraphPad
PrismW software (GraphPad Software Inc., La Jolla,
California, USA). Statistical significance of compari-
sons between two independent groups was determined
with the two-tailed Mann–Whitney U test. The com-
parison between paired samples was performed with
the Wilcoxon signed-rank test. The accuracy of the
markers was determined with receiver operator char-
acteristic curves (ROC). The statistical significance of
the difference between two areas under the ROC
curves was calculated by the method of DeLong et al.
and performed with MedCalcW software (MedCalc
Software, Mariakerke, Belgium) [35]. Significant p-
values were ranked as p < 0.05 (*), p < 0.01 (**) and
p < 0.001 (***).Additional files
Additional file 1: Table S1. Comparison of expression levels in male
versus female patients with Mann-Whitney test. *: p < 0.05.
Additional file 2: Table S2. Comparison of expression levels in colon
carcinoma with tumor grade low versus moderate versus high with
Kruskal Wallis test. *: p < 0.05.
Additional file 3: Table S3. Comparison of expression levels in colon
carcinoma with Dukes classification A versus B versus C versus D with
Kruskal Wallis test. *: p < 0.05.
Additional file 4: Table S4. Comparison of expression levels in healthy
colon and colon carcinoma samples from different tumor sites (caecum
and Valve of Bauhin versus colon ascendens, transversum, descendens
and hepatic flexure versus sigmoid) with Kruskal Wallis test. *: p < 0.05;
**:p < 0.01. n/a: not applicable.
Additional file 5: Table S5. Comparison of expression levels in patients
younger than 70 years or of 70 years versus patients older than 70 with
Mann-Whitney test.
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